What is the ROCE (Return on Capital Employed) of Neovacs this year?
The ROCE of Neovacs is -0.14 undefined this year.
Neovacs ROCE 2024
Neovacs ROCE
-0.14
Ticker
ALNEV.PA
ISIN
FR0004032746
WKN
A1CVKR
In 2024, Neovacs's return on capital employed (ROCE) was -0.14, a 10.08% increase from the -0.13 ROCE in the previous year.
Neovacs Aktienanalyse
What does Neovacs do?
Neovacs SA is a French biotechnology company specializing in the development of immunotherapies for the treatment of autoimmune diseases and cancer. It was founded in 1993 by Pierre Vandepapeliere and is headquartered in Paris. The company has a history of groundbreaking discoveries and continuous innovation. Its business model is based on the combination of cutting-edge research and the development of customized therapies for the treatment of autoimmune diseases and cancer. Neovacs SA identifies specific proteins that trigger an immune response against the body's own cells and tissues, and develops Kinoid vaccines to neutralize these proteins and stop the autoimmune reaction. It is also specialized in the development of immunotherapies for the treatment of cancer. The main divisions of Neovacs SA are clinical development, regulatory affairs, and the manufacturing of Kinoid vaccines. It has achieved an impressive track record in the clinical development of Kinoid vaccines and collaborates with leading universities, hospitals, and research institutions to support its research and development activities. The company currently offers a range of different Kinoid vaccines for the treatment of autoimmune diseases, including a product for the treatment of lupus, a product for the treatment of rheumatoid arthritis, and a product for the treatment of chronic hepatitis B. All of these products are currently in Phase 2 development. Another important product being developed by Neovacs SA is an immunotherapeutic for the treatment of cancer. Known as TNF-Kinoid, the product aims to enhance the body's immune defense against cancer cells and inhibit tumor growth. It has shown promising results in Phase 1 clinical development and is currently in Phase 2 development. Neovacs SA is a strong and growing company in a rapidly evolving sector of biotechnology. It has an impressive track record in the clinical development of immunotherapies for the treatment of autoimmune diseases and cancer, and is well-positioned to continue making significant contributions to healthcare. Neovacs ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Neovacs's Return on Capital Employed (ROCE)
Neovacs's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Neovacs's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Neovacs's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Neovacs’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Neovacs stock
How has the ROCE (Return on Capital Employed) of Neovacs developed compared to the previous year?
The ROCE of Neovacs has increased by 10.08% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Neovacs?
A high Return on Capital Employed (ROCE) indicates that Neovacs has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Neovacs?
A low ROCE (Return on Capital Employed) can indicate that Neovacs has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Neovacs impact the company?
An increase in the ROCE of Neovacs can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Neovacs affect the company?
A decrease in ROCE of Neovacs can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Neovacs?
Some factors that can affect Neovacs's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Neovacs so important for investors?
The ROCE of Neovacs is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Neovacs take to improve the ROCE?
To improve the ROCE, Neovacs can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Neovacs pay?
Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.
What is the dividend yield of Neovacs?
The current dividend yield of Neovacs is .
When does Neovacs pay dividends?
Neovacs pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neovacs?
Neovacs paid dividends every year for the past 0 years.
What is the dividend of Neovacs?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neovacs located?
Neovacs is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neovacs from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Neovacs pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Neovacs in the year 2023?
In the year 2023, Neovacs distributed 0 EUR as dividends.
In which currency does Neovacs pay out the dividend?
The dividends of Neovacs are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neovacs
Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
